SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Hepatitis
An SI Board Since March 2001
Posts SubjectMarks Bans
312 28 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
212Re: Tidbits on the all-oral HCV cocktail ITMN’s Dan Welch gave some tidbits on DewDiligence_on_SI-11/11/2008
211Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48tnsaf-11/3/2008
210NS4B Inhibitor Show Promise Against HCV: siliconinvestor.comDewDiligence_on_SI-9/1/2008
209<b>iTherX Pharmaceuticals Appoints Scientific Advisory Board for HCV</bDewDiligence_on_SI-8/19/2008
208HCV: Most Likely to Succeed (IMHO) <i>[Based on today’s news, I’ve upgradDewDiligence_on_SI-8/4/2008
207Devastating Risk of Undertreating HCV [graphic] Source: VRTX GS webcast (6/11/DewDiligence_on_SI-6/23/2008
206VRUS admitted (on today’s MS webcast) that the data showing SVR potential for ClDewDiligence_on_SI-4/30/2008
205HCV: Most Likely to Succeed (IMHO): siliconinvestor.comDewDiligence_on_SI-4/1/2008
204Basic research: a tool that stops the assembly pathway of HC virion pubmedcentidos-3/21/2008
203Europe’s CHMP Approves Viread for HBV: siliconinvestor.comDewDiligence_on_SI-3/19/2008
202OctoPlus, Biolex Commence US Phase-2a Trial of Locteron in HCV: siliconinvestorDewDiligence_on_SI-2/7/2008
201Baraclude has surpassed Hepsera as the leading HBV drug in worldwide sales: 4Q0DewDiligence_on_SI-1/31/2008
200HCV: Most Likely to Succeed (IMHO): siliconinvestor.comDewDiligence_on_SI-1/25/2008
199Re: GS9190 non-nuke for HCV GILD’s CSO, Norbert Bischofberger, said on today’s DewDiligence_on_SI-1/23/2008
198Some articles relevant to this thread; some are free until June 2008. Message 24tnsaf-12/26/2007
197Virologic Monitoring in Hepatitis B: Tools for Determining Treatment Candidacy aDewDiligence_on_SI-11/26/2007
196Inhibitex Obtains License To HCV Polymerase Inhibitors Potent Nucleoside Analoguscaram(o)uche-11/20/2007
195Globeimmune gave a very interesting presentation at the Rodman conference, incluDewDiligence_on_SI-11/7/2007
194Human combinatorial libraries yield rare antibodies that broadly neutralize hepatnsaf-10/4/2007
193Updated HCV Scorecard: <b><u>Programs killed during 2007</u>&DewDiligence_on_SI-8/10/2007
192Monthly ‘street’ prices for HBV drugs: siliconinvestor.comDewDiligence_on_SI-7/30/2007
191Data looks more than pretty good. Here's the PR. Press Release Source:rkrw-7/26/2007
190Biolex Reports Phase-2a Results of Locteron in HCV: tinyurl.com The data look pDewDiligence_on_SI-7/26/2007
189Father-to-Child HBV Transmission Reported in the Journal of Medical Virology: DewDiligence_on_SI-7/25/2007
188Competitive landscape in HBV: siliconinvestor.comDewDiligence_on_SI-7/16/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News